Profile: ImmunoVaccine Technologies Inc. is a pre-clinical stage private biotechnology company developing therapeutic cancer and prophylactic infectious disease vaccines for human health. Our Vaccimax® platform is able to stimulate an earlier, more powerful, long lasting antibody & cellular immune response, and it can also able to reduce the number of doses required for protection against infectious diseases like influenza. We focus on building a strong pipeline of vaccine products that include therapeutic cancer and prophylactic infectious disease products at different stages of pre-clinical & clinical development.